NASDAQ:CRMD - CorMedix Stock Price, News, & Analysis

$7.77
-0.20 (-2.51 %)
(As of 06/25/2019 07:42 AM ET)
Today's Range
$7.77
Now: $7.77
$8.10
50-Day Range
$6.00
MA: $7.11
$8.10
52-Week Range
$1.05
Now: $7.77
$13.70
Volume380,433 shs
Average Volume522,549 shs
Market Capitalization$185.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRMD
CUSIPN/A
Phone908-517-9500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$185.03 million
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

CorMedix (NASDAQ:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the NASDAQ under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc (NASDAQ:CRMD) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.07. The business earned $0.16 million during the quarter, compared to analyst estimates of $0.06 million. View CorMedix's Earnings History.

When is CorMedix's next earnings date?

CorMedix is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for CorMedix.

What price target have analysts set for CRMD?

1 analysts have issued 12 month price objectives for CorMedix's stock. Their predictions range from $6.00 to $6.00. On average, they anticipate CorMedix's stock price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 22.8%. View Analyst Price Targets for CorMedix.

What is the consensus analysts' recommendation for CorMedix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.

Has CorMedix been receiving favorable news coverage?

News stories about CRMD stock have been trending somewhat negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CorMedix earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for CorMedix.

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include Gigamon (GIMO), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), Conatus Pharmaceuticals (CNAT), Internap (INAP), HyreCar (HYRE), Globalstar (GSAT), ANI Pharmaceuticals (ANIP), AVEO Pharmaceuticals (AVEO) and Geron (GERN).

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:
  • Mr. Khoso Baluch, CEO & Director (Age 60)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 62)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 74)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 39)
  • Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $7.77.

How big of a company is CorMedix?

CorMedix has a market capitalization of $185.03 million. View Additional Information About CorMedix.

What is CorMedix's official website?

The official website for CorMedix is http://www.cormedix.com/.

How can I contact CorMedix?

The company can be reached via phone at 908-517-9500.


MarketBeat Community Rating for CorMedix (NASDAQ CRMD)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel